Stockreport

Eli Lilly doubles down on Oblique partnership for antibody generation [Yahoo! Finance]

AbCellera Biologics Inc. - Common Shares  (ABCL) 
PDF Building on the existing agreement from November 2023, Eli Lilly will continue to use Oblique's AbiProt platform to discover antibodies. Specifically, Sweden-based Obli [Read more]